Assessment of the risk factors and various patient related attributes influencing hemodialysis

Paper Details

Research Paper 01/04/2019
Views (331) Download (12)

Assessment of the risk factors and various patient related attributes influencing hemodialysis

Samreen Tanveer, Mehran Ashfaq, Rashida Parveen, Kanwal Ashiq, Mehwish Qayyum, Mayyda Bajwa, Sana Ashiq, Afshan Arshad
Int. J. Biosci.14( 4), 238-247, April 2019.
Certificate: IJB 2019 [Generate Certificate]


Renal failure is associated with a variety of comorbid conditions and negatively affects the patients’ quality of life. The aim of current study was to assess various patient related attributes effecting on the efficiency of hemodialysis accompanied by vital parameters such as predominant cause of end stage renal disease, intradialytic complications, determination of diet plan impact on hemodialytic patients and analysis of hemodialysis as only treatment of choice in renal failure except kidney transplant. Data of 50 patients were collected from Sheikh Zayed hospital dialysis unit. Statistical analysis was done by SPSS version 22. About 40% patients presented a family history of renal disorders, 70% patients undertook peritoneal dialysis prior to hemodialysis, A-V fistula at lower arm was most recommended location for vascular access, 10% patients used heparin during hemodialysis, 60% patients were on iron and vitamin intake, 80% patients were on limited intake of sodium and fluid, 76% patients were taking potassium and calcium supplements and 80% patients were taking albumin and proteins. About 96% patients were taking Eprex injection and 80% patients were vaccinated. Joint pain and muscular weakness were major complications and 60% patients showed intension of kidney transplant to improve their quality of life. Hereditary factors, diet, fluid intake and lack of awareness play a key role in the incidence of renal failure. If awareness of renal disorders and hemodialysis amongst population could be developed then early diagnosis and better treatment of renal failure will be done along with improvement in the patient’s quality of life.


Alter M J, Favero MS, Maynard JE. 1986. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. The Journal of infectious diseases 153, 1149-1151.

Bay WH, Van Cleef S, Owens M. 1998. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. American journal of nephrology 18, 379-383.

Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GrM. 1998. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32, 570-574.

Block GA., Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. 2004. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology 15, 2208-2218.

Brownlee M. 2001.Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813.

Brunner F, Selwood N. 1992. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. Kidney international. Supplement 38, S4-15.

Carter J, Lee C, Weinstein R. 2000. Renal medicine and renal transplantation. transplantation 35, E101-E104.

Choi HY, Ha SK. 2013. Potassium balances in maintenance hemodialysis. Electrolytes & Blood Pressure 11, 9-16.

Cronin RE, Reilly RF. 2010. Unfractionated heparin for hemodialysis: still the best option. Paper presented at the Seminars in dialysis.

Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Kjellstrand CM. 1997. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. American journal of kidney diseases 30, 334-342.

Fishbane S, Berns JS. 2005. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney international 68, 1337-1343.

Foley RN, Collins AJ. 2007. End-stage renal disease in the United States: an update from the United States Renal Data System. Journal of the American Society of Nephrology 18, 2644-2648.

Freedman BI, Spray BJ, Tuttle, AB, Buckalew Jr VM. 1993. The familial risk of end-stage renal disease in African Americans. American journal of kidney diseases 21, 387-393.

Fujisawa M, Ichikawa Y, Yoshiya K, Isotani S, Higuchi A, Nagano S, Kamidono S. 2000. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology 56, 201-206.

Group FT. 2010. In-center hemodialysis six times per week versus three times per week. New England Journal of Medicine 363, 2287-2300.

Heaf JG, Løkkegaard H, Madsen M. 2002. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrology Dialysis Transplantation 17, 112-117.

Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, D’Agati VD. 2010. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. Journal of the American Society of Nephrology 21, 163-172.

Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. 1994. Amino acid and albumin losses during hemodialysis. Kidney international 46, 830-837.

Kanwal A, Khurrum R, Sana A, Ahlam S. 2017. Influence of osteoporosis on quality of life and current strategies for its management and treatment. GSC Biological and Pharmaceutical Sciences 1, 34-40.

Kleinman KS, Coburn JW. 1989. Amyloid syndromes associated with hemodialysis. Kidney international 35, 567-575.

Kosmadakis G, Da Costa Correia E, Carceles O, Somda F, Aguilera D. 2014. Vitamins in dialysis: who, when and how much? Renal failure 36, 638-650.

Krüger S, Müller-Steinhardt M, Kirchner H, Kreft B. 2001. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. American journal of kidney diseases 38, 1264-1270.

Lai KN, Wang AY, Ho K, Szeto C C, Li M, Wong LK, Alex W. 1996.Use of low-dose low molecular weight heparin in hemodialysis. American journal of kidney diseases 28, 721-726.

López-Gómez JM, Pérez-Flores I, Jofré R, Carretero D, Rodríguez-Benitez P, Villaverde M, Ayus JC. 2004. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. Journal of the American Society of Nephrology 15, 2494-2501.

Maynard JC, Cruz C, Kleerekoper M, Levin, NW. 1986. Blood pressure response to changes in serum ionized calcium during hemodialysis. Annals of internal medicine 104, 358-361.

Murphy SW, Foley RN, Barrett BJ, Kent GM, Morgan J, Barré P, Handa SP. 2000. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney international 57, 1720-1726.

Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergström J. 2002. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. Journal of the American Society of Nephrology 13, S28-S36.

Ritz E, Rychlík I, Locatelli F, Halimi S. 1999. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. American journal of kidney diseases 34, 795-808.

Scharpé J, Peetermans W E, Vanwalleghem J, Maes B, Bammens B, Claes K, Evenepoel P. 2009. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. American journal of kidney diseases 54, 77-85.

Shinoda T, Komatsu M, Aizawa T, Shirota T, Yamada T, Ehara T, Mizukami E. 1989. Intestinal pseudo-obstruction due to dialysis amyloidosis. Clinical nephrology 32, 284-289.

Simmons RG, Anderson C, Kamstra L. 1984.Comparison of quality of life of patients on continuous ambulatory peritoneal dialysis, hemodialysis, and after transplantation. American journal of kidney diseases 4, 253-255.

Snyder JJ, Foley RN, Gilbertson DT, Vonesh, EF, Collins AJ. 2004.Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States. Journal of the American Society of Nephrology 15, 174-179.

Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W, Group DVTS. 1984. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. New England Journal of Medicine 311, 496-501.

Waikar SS, Curhan GC, Brunelli SM. 2011. Mortality associated with low serum sodium concentration in maintenance hemodialysis. The American journal of medicine 124, 77-84.

Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Glassock R. 2002. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. Jama 288, 2421-2431.